

Dear Editors and Reviewers:

Thank you for arranging a timely review for our manuscript entitled “An extremely rare adverse drug reaction: acute thrombocytopenia after anticoagulation with rivaroxaban: A case report”. The comments are valuable and helpful for revising and improving our paper. We have carefully studied the reviewers’ critical comments and suggestions, responded to these comments point-by-point, and revised the manuscript accordingly. All revisions to the paper are highlighted in blue and the responses to the reviewers’ comments are as follows:

The first part of the title (An extremely rare adverse drug reaction) is unnecessary. Shorter title is better for getting citation. The period from starting rivaroxaban treatment to development thrombocytopenia should be mentioned in the abstract. Mechanism of action rivaroxaban has to be mentioned in the Introduction. There are extensive laboratory data which are unrelated to thrombocytopenia or rivaroxaban. Concise laboratory values is more suitable for a case report

Response: We deleted the unnecessary part and renamed the article as “Acute thrombocytopenia after anticoagulation with rivaroxaban: A case report”. We mentioned the period from starting rivaroxaban treatment to development thrombocytopenia in the abstract. We mentioned the mechanism of action rivaroxaban was mentioned in the Introduction. The irrelevant laboratory data as serum creatinine, ALT and AST levels were deleted. In addition, we added a figure to the article.